Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 901, Hoe
2. A21 Gly B31 Arg B32 Arg Insulin
3. A21-gly-b31-arg-b32-arg-insulin
4. Basaglar
5. Glargine
6. Glargine, Insulin
7. Glargine-aglr, Insulin
8. Hoe 901
9. Hoe-901
10. Hoe901
11. Insulin Glargine
12. Insulin Glargine-aglr
13. Insulin Glargine-yfgn
14. Insulin, Gly(a21)-arg(b31,b32)
15. Insulin, Glycyl(a21)-arginyl(b31,b32)
16. Lantus
17. Lantus Solostar
18. Rezvoglar
19. Semglee
20. Solostar, Lantus
1. Gtpl7572
2. Hoe901
3. Hoe-901
Molecular Weight | 6063 g/mol |
---|---|
Molecular Formula | C267H404N72O78S6 |
XLogP3 | -14.1 |
Hydrogen Bond Donor Count | 85 |
Hydrogen Bond Acceptor Count | 92 |
Rotatable Bond Count | 191 |
Exact Mass | 6060.8251182 g/mol |
Monoisotopic Mass | 6058.8184085 g/mol |
Topological Polar Surface Area | 2590 Ų |
Heavy Atom Count | 423 |
Formal Charge | 0 |
Complexity | 15300 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 53 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Lantus |
PubMed Health | Insulin Glargine |
Drug Classes | Antidiabetic, Insulin, Long Acting |
Drug Label | LANTUS (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenter... |
Active Ingredient | Insulin glargine recombinant |
Dosage Form | Injectable |
Route | Injection |
Strength | 100 units/ml |
Market Status | Prescription |
Company | Sanofi Aventis Us |
2 of 2 | |
---|---|
Drug Name | Lantus |
PubMed Health | Insulin Glargine |
Drug Classes | Antidiabetic, Insulin, Long Acting |
Drug Label | LANTUS (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenter... |
Active Ingredient | Insulin glargine recombinant |
Dosage Form | Injectable |
Route | Injection |
Strength | 100 units/ml |
Market Status | Prescription |
Company | Sanofi Aventis Us |
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RLD :
TE Code :
Brand Name : LANTUS
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100 UNITS/ML
Approval Date :
Application Number : 21081
RX/OTC/DISCN :
RLD :
TE Code :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RLD :
TE Code :
Brand Name : LANTUS SOLOSTAR
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 300 UNITS/3ML (100 UNITS/ML)
Approval Date :
Application Number : 21081
RX/OTC/DISCN :
RLD :
TE Code :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RLD :
TE Code :
Brand Name : TOUJEO SOLOSTAR
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 450 UNITS/1.5ML (300 UNITS/ML)
Approval Date :
Application Number : 206538
RX/OTC/DISCN :
RLD :
TE Code :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RLD :
TE Code :
Brand Name : TOUJEO MAX SOLOSTAR
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 900 UNITS/3ML (300 UNITS/ML)
Approval Date :
Application Number : 206538
RX/OTC/DISCN :
RLD :
TE Code :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RLD :
TE Code :
INSULIN GLARGINE; LIXISENATIDE
Brand Name : SOLIQUA 100/33
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML)
Approval Date :
Application Number : 208673
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : BASAGLAR
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 300 UNITS/3ML (100 UNITS/ML)
Approval Date :
Application Number : 205692
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : REZVOGLAR
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 3ML(100UNITS/ML)
Approval Date :
Application Number : 761215
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SEMGLEE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100 UNITS/ML
Approval Date :
Application Number : 210605
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SEMGLEE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10ML(100UNITS/ML)
Approval Date :
Application Number : 761201
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SEMGLEE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 3ML(100UNITS/ML)
Approval Date :
Application Number : 761201
RX/OTC/DISCN :
RLD :
TE Code :
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Brand Name : LANTUS
Patent Number : 1339044
Filing Date : 1989-09-29
Strength per Unit : 100 IU / ml
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Brand Name : LANTUS
Patent Number : 1339044
Filing Date : 1989-09-29
Strength per Unit : 100 IU / ml
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Brand Name : LANTUS
Patent Number : 1339044
Filing Date : 1989-09-29
Strength per Unit : 100 U / mL
Dosage Form : Solution (10 mL Vial)
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Patent Expiration Date : 2023-06-05
Date Granted : 2012-07-24
Brand Name : LANTUS
Patent Number : 2490116
Filing Date : 2003-06-05
Strength per Unit : 100 U / mL
Dosage Form : Solution (10 mL Vial)
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2023-06-05
Date Granted : 2012-07-24
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Brand Name : LANTUS
Patent Number : 1339044
Filing Date : 1989-09-29
Strength per Unit : 100 U / ML
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Brand Name : LANTUS
Patent Number : 1339044
Filing Date : 1989-09-29
Strength per Unit : 100 U / mL
Dosage Form : solution
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2014-04-01
Date Granted : 1997-04-01
Patent Expiration Date : 2031-05-18
Date Granted : 2015-09-29
Brand Name : TOUJEO SOLOSTAR
Patent Number : 2792669
Filing Date : 2011-05-18
Strength per Unit : 300 unit / mL - (450 IU)
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2031-05-18
Date Granted : 2015-09-29
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?